Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Repligen Corp (NQ: RGEN )

126.97 +3.16 (+2.55%)
Streaming Delayed Price Updated: 1:03 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repligen Corp

< Previous 1 2 3 4 5 6 Next >
Humana, Waters, e.l.f. Beauty, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Wednesday. Here are some big stocks recording gains in today’s session. Powell Industries, Inc. (NASDAQ: POWL) shares jumped... 
Via Benzinga
Top 5 Health Care Stocks That May Collapse In July
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Repligen
Via Benzinga
Over $6M Bet On This Financial Services Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mixed on Monday, there were a few notable insider trades. 
Via Benzinga
Looking Into Repligen's Return On Capital Employed
Via Benzinga
Why Repligen Stock Is Sinking Today
Investors appear to be anticipating an underwhelming first-quarter report from the bioprocessing company. 
Via The Motley Fool
Why Shares of Repligen Rose This Week
The company is coming off a solid third quarter and is getting noticed by analysts. 
Via The Motley Fool
Despite Attractive End Markets, Analyst Outlines Concerns For Repligen Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2023
Via Benzinga
Repligen Expects Slower Growth In APAC, Builds Portfolio On Heels Of FlexBiosys Deal
Repligen Corp (NASDAQ: RGEN) reported Q1 FY23 sales of $182.66 million, down 12% Y/Y as reported,  
Via Benzinga
Repligen Beefs Up Process Analytics Portfolio With DRS Daylight Solutions Pact
Via Benzinga
Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
Via Benzinga
This Analyst Is Bullish on Repligen's FlexBiosys Acquisition for Fluid Management Portfolio
Repligen Inc (NASDAQ: RGEN) agreed to acquire FlexBiosys Inc to build its Fluid Management franchise and add a full range of single-use bioprocessing bags and assemblies.  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023
Via Benzinga
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
Via Benzinga
Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover
Danaher is reportedly looking to add to its wheelhouse to compete with Thermo. 
Via Investor's Business Daily
Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday
U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Repligen Earnings Perspective: Return On Capital Employed
Pulled from Benzinga Pro data, Repligen (NASDAQ:RGEN) posted Q3 earnings of $40.41 million, an increase from Q2 of 18.96%. Sales dropped to $200.74 million, a 3.32% decrease between quarters. 
Via Benzinga
Recap: Repligen Q3 Earnings
Repligen (NASDAQ:RGEN) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Repligen beat estimated earnings by... 
Via Benzinga
Abbott Laboratories, M&T Bank And Some Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining more than 100 points on Wednesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Earnings Scheduled For November 1, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. 
Via Benzinga
Why Olaplex Shares Dipped Around 57%; Here Are 75 Biggest Movers From Yesterday
Gainers Amprius Technologies, Inc. (NYSE: AMPX) jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million cost-sharing grant from the U.S. Department of... 
Via Benzinga
Why United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday's Mid-Day Session
Gainers SenesTech, Inc. (NASDAQ: SNES) shares jumped 102.6% to $0.47 after declining over 3% on Tuesday. SenesTech, during August, posted a Q2 loss of $0.21 per share. 
Via Benzinga
MarketBeat: Week in Review 9/12 – 9/16
In volatile markets, rely on MarketBeat to keep you focused on your investment objectives. Here are some of our most popular articles from this week 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Why Medical Products Maker Repligen May Be A Potential Buy
Medical products maker Repligen has a long history of trouncing sales and earnings views, and it just boosted its full-year sales guidance. Is the stock a buy? 
Via MarketBeat
Top-Rated Stocks: Lantheus Stock Sees Composite Rating Climb To 96
Top-rated Lantheus stock saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 94 to 96. 
Via Investor's Business Daily
Golden Cross Appears Before Repligen Investors
If history is any guide, there may be good fortune ahead for shares of Repligen (NASDAQ:RGEN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
Glaukos Stock Scores Rising Price Performance With Jump To 91 RS Rating
On Tuesday, Glaukos stock hit an key technical milestone, with its Relative Strength Rating climbing to 91, up from 87 the day before. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.